SignatureFD’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

SignatureFD’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-828	Closed	-$22K	–	2129
2018 Q3	$22K	Hold	828	–	–	﹤0.01%	1148
2018 Q2	$17K	Buy	+828	New	+$17.8K	﹤0.01%	1229
2016 Q4	–	Sell	-100	Closed	-$1K	–	1408
2016 Q3	$1K	Buy	+100	New	+$1.18K	﹤0.01%	1559

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SignatureFD's MNTA Position: Q4 2018 in Review

SignatureFD sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2018, closing a stake of 828 shares — an estimated $22K sold.

SignatureFD first reported a position in MNTA in Q3 2016 and held it in 3 quarters. The position peaked at $22K in Q3 2018. 158 funds tracked by Wall St. Rank hold MNTA as of Q4 2018.

SignatureFD reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
SignatureFD sold 828 Momenta Pharmaceuticals, Inc. shares in Q4 2018, an estimated $22K.
SignatureFD first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
SignatureFD's Momenta Pharmaceuticals, Inc. position peaked at $22K in Q3 2018.
158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2018.

Based on SignatureFD's 13F filing for Q4 2018, filed 13 Feb 2019.